High Pointe Capital Management’s Charles River Laboratories CRL Stock Holding History

High Pointe Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-12,560	Closed	-$1.01M	–	86
2015 Q4	$1.01M	Sell	12,560 -350	-3%	-$25.2K	0.5%	68
2015 Q3	$820K	Sell	12,910 -11,030	-46%	-$792K	0.39%	92
2015 Q2	$1.68M	Sell	23,940 -13,130	-35%	-$972K	0.6%	72
2015 Q1	$2.94M	Sell	37,070 -8,280	-18%	-$611K	1.05%	20
2014 Q4	$2.89M	Sell	45,350 -5,700	-11%	-$357K	1.27%	9
2014 Q3	$3.05M	Buy	+51,050	New	+$2.92M	1.32%	6
2014 Q2	–	Sell	-54,950	Closed	-$3.32M	–	162
2014 Q1	$3.32M	Hold	54,950	–	–	1.28%	8
2013 Q4	$2.92M	Hold	54,950	–	–	1.15%	12
2013 Q3	$2.54M	Buy	+54,950	New	+$2.52M	1.02%	21

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

High Pointe Capital Management's CRL Position: Q1 2016 in Review

High Pointe Capital Management sold out of Charles River Laboratories (CRL) in Q1 2016, closing a stake of 12,560 shares — an estimated $1.01M sold.

High Pointe Capital Management first reported a position in CRL in Q3 2013 and held it in 9 quarters. The position peaked at $3.32M in Q1 2014. 264 funds tracked by Wall St. Rank hold CRL as of Q1 2016.

High Pointe Capital Management reported no remaining Charles River Laboratories position as of Q1 2016 after selling out during the quarter.
High Pointe Capital Management sold 12,560 Charles River Laboratories shares in Q1 2016, an estimated $1.01M.
High Pointe Capital Management first reported a position in Charles River Laboratories in Q3 2013 and held it in 9 quarters.
High Pointe Capital Management's Charles River Laboratories position peaked at $3.32M in Q1 2014.
264 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2016.

Based on High Pointe Capital Management's 13F filing for Q1 2016, filed 5 May 2016.